Final multivariable models for DFS and OS in Black and White AYA patients with AML who received consolidative chemotherapy, and for OS in a combined group of patients who received either consolidation with chemotherapy or allogeneic HSCT in first CR off-protocol
| Variable . | Categories . | P∗ . | HR (95% CI) . |
|---|---|---|---|
| DFS (no allogeneic HSCT in first CR) | |||
| Race | White vs Black | .04 | 0.70 (0.50, 0.98) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.32 (1.19, 1.48) |
| CBF-AML | Yes vs no | <.001 | 0.51 (0.39, 0.67) |
| OS (no allogeneic HSCT in first CR) | |||
| Race | White vs Black | <.001 | 0.57 (0.43, 0.76) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.31 (1.20, 1.43) |
| CBF-AML | Yes vs no | <.001 | 0.42 (0.32, 0.56) |
| OS (including allogeneic HSCT in first CR) | |||
| Race | White vs Black | <.001 | 0.55 (0.42, 0.73) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.20 (1.12, 1.29) |
| CBF-AML | Yes vs no | <.001 | 0.44 (0.33, 0.58) |
| Variable . | Categories . | P∗ . | HR (95% CI) . |
|---|---|---|---|
| DFS (no allogeneic HSCT in first CR) | |||
| Race | White vs Black | .04 | 0.70 (0.50, 0.98) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.32 (1.19, 1.48) |
| CBF-AML | Yes vs no | <.001 | 0.51 (0.39, 0.67) |
| OS (no allogeneic HSCT in first CR) | |||
| Race | White vs Black | <.001 | 0.57 (0.43, 0.76) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.31 (1.20, 1.43) |
| CBF-AML | Yes vs no | <.001 | 0.42 (0.32, 0.56) |
| OS (including allogeneic HSCT in first CR) | |||
| Race | White vs Black | <.001 | 0.55 (0.42, 0.73) |
| White blood cell count | Continuous, 50-unit increase | <.001 | 1.20 (1.12, 1.29) |
| CBF-AML | Yes vs no | <.001 | 0.44 (0.33, 0.58) |
P values are from Cox proportional hazard models. An HR >1 (<1) indicates higher (lower) risk for the categorical variable listed first or higher values of a continuous variable.